Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy

Cardiovascular Therapeutics
Helena VaverkovaPhilippe Brudi

Abstract

This post hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) or rosuvastatin 10 mg (ROSUVA) in uncontrolled high-risk hypercholesterolemic patients with/without type 2 diabetes mellitus (T2DM) despite statin monotherapy. Patients (n = 618) at high risk for coronary vascular disease with elevated LDL-C ≥100 and ≤190 mg/dL despite use of statins were randomized 1:1 to double-blind EZE/SIMVA 10/20 mg or ROSUVA 10 mg for 6 weeks. Patients were classified as having T2DM based on ≥1 of the following: diagnosis of T2DM, antidiabetic medication, or FPG ≥126 mg/dL. This analysis evaluated percent changes from baseline in lipids among patients with (n = 182) and without T2DM (n = 434). EZE/SIMVA was more effective than ROSUVA at lowering LDL-C, TC, non-HDL-C, and apo B in the overall study population and within both subgroups. Numerically, greater between-treatment reductions in LDL-C, TC, non-HDL-C, and apo B were seen in patients with T2DM versus those without T2DM. A significant interaction (P= 0.015) was seen for LDL-C indicating that patients with T2DM achieved larger between-group reductions versus those without T2DM. Switching to EZE/SIMVA 10/20 mg versus ROSUVA 10 mg provided superior lip...Continue Reading

References

May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Aug 28, 2002·Diabetes Care·Piia P SimonenTatu A Miettinen
Dec 25, 2003·Diabetes Care·Steven M Haffner, UNKNOWN American Diabetes Association
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Sep 1, 2004·JAMA : the Journal of the American Medical Association·James A de LemosUNKNOWN Investigators
Sep 11, 2004·Journal of the American College of Cardiology·Scott M GrundyUNKNOWN Coordinating Committee of the National Cholesterol Education Program
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Nov 17, 2005·JAMA : the Journal of the American Medical Association·Terje R PedersenUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
Apr 22, 2006·Cardiology in Review·Maria P Solano, Ronald B Goldberg
Aug 1, 2006·Journal of the American College of Cardiology·Christopher P CannonEugene Braunwald
Jan 15, 2008·Atherosclerosis·Laurent LaforestEric Van Ganse
Aug 12, 2008·Atherosclerosis. Supplements·Gerald H Tomkin
Feb 21, 2009·Nature Clinical Practice. Endocrinology & Metabolism·Arshag D Mooradian
Mar 17, 2009·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Kornelia KotsevaUNKNOWN EUROASPIRE Study Group
May 20, 2009·Clinical Biochemistry·Helena VaverkovaJiri Frohlich

❮ Previous
Next ❯

Citations

Jul 29, 2010·Lipids in Health and Disease·Carlo M RotellaGian Franco Gensini
Oct 15, 2019·International Journal of Clinical Practice·Allison ClyneBrian H May
Nov 20, 2016·Cardiovascular Therapeutics·Samantha A HollingworthSusan E Tett
Jul 1, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Kittipot SirichaiwetchakoonGriangsak Eumkeb

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.